Overview

Clinical Trial to Assess the Safety and Efficacy of Sodium Stibogluconate (SSG) and AmBisome® Combination, Miltefosine and AmBisome® and Miltefosine Alone for the Treatment Visceral Leishmaniasis in Eastern Africa

Status:
Completed

Trial end date:
2011-06-01

Target enrollment:

Participant gender:

Summary

This study is to assess if shorter combinations of SSG plus single dose AmBisome®, Miltefosine plus single dose AmBisome® and Miltefosine alone are effective in treating visceral leishmaniasis in Eastern Africa.

Phase:

Phase 2

Details

Lead Sponsor:

Drugs for Neglected Diseases

Collaborators:

Gilead Sciences
Paladin Laboratories Inc
Paladin Labs Inc.

Treatments:

Amphotericin B
Antimony Sodium Gluconate
Liposomal amphotericin B
Miltefosine